Yan Zhang sold $4 of EVFM
CFO at Evofem Biosciences, Inc.. 104 shares at an average of $0.04, traded Jan 12, 2024, filed Jan 12, 2024.
Score components
- +22RoleCFO
- 0Trade size$4 at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -25.0%, 3m -62.5%, 6m -72.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-002231, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2024 | SOpen-market sale Common Stock | -104 | $0.04 | $4 | 0 | Jan 12, 2024 |
Related signals
Other insiders at Evofem Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | EVFMsell Evofem Biosciences, Inc. | Kim P. Kamdar director | $6 10 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.